Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

umulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients.

Study Methodology and Results

116 CLL patients were enrolled in the study in a series of treatment cohorts, which included patients who were never treated (treatment-nave); those who had received two or more prior therapies (relapsed/refractory); those who had relapsed within two years of treatment (high-risk); and those over age 65. Two oral dosing regimens (420 mg or 840 mg) of ibrutinib were used daily. The primary goal of the study was to determine the safety of the low and high doses. Secondary objectives included efficacy, measures of the intensity of the drug's effect in the body and the long-term safety of administering continuously until relapse.

The majority of adverse effects were diarrhea (54%), fatigue (29%), upper respiratory tract infection (29%), rash (28%), nausea (26%) and arthralgias (25%). Hematologic toxicity ≥ Gr 3 was relatively infrequent. There was no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months. Estimated 22 month progression free survival for the 85 relapsed or refractory and high-risk patients was 76 percent and 96 percent for treatment-nave patients. Estimated 22 month overall survival for the 85 relapsed or refractory patients and high-risk patients was 85 percent and 96 percent for treatment-nave patients. Funding from Pharmacyclics, Inc., supports this clinical trial.


'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... that HIV and its monkey equivalent, SIV, gain a ... making it difficult to completely eliminate the virus even ... report that SIV can become entrenched in tissues fewer ... detectable in blood plasma (the liquid part) or blood ... Ph.D., of Beth Israel Deaconess Medical Center and the ...
(Date:7/21/2014)... CA (PRWEB) July 21, 2014 Ticket Down ... Manchester United tickets at the Rose Bowl . One of ... will be taking part in the 2014 Guinness International Champions Cup, ... The popular member of the English Premier League will get a ... travel to the Rose Bowl in Pasadena, Calif. for the Chevrolet ...
(Date:7/21/2014)... July 21, 2014 The New ... mesh lawsuits ( http://www.transvaginalmeshlawsuithelp.com/ ) filed against ... awarded last year to the Plaintiff in the ... Judge Carol Higbee of Atlantic County Superior Court ... judgment notwithstanding the verdict on July 15th, noting ...
(Date:7/21/2014)... July 21, 2014 (HealthDay News) -- A recently developed molecular ... in the lab. The team of scientists at Temple ... one day lead to a permanent treatment for HIV. They ... a vaccine to offer protection against the disease in the ... system, removal of the virus is required in order to ...
(Date:7/21/2014)... By Dennis Thompson ... (HealthDay News) -- Despite recent advances in preventing heart ... have occurred among middle-aged adults -- especially women, a ... young and middle-aged adults have remained stable during the ... a better than 20 percent decline in heart attacks, ...
Breaking Medicine News(10 mins):Health News:NIH-supported scientists demonstrate very early formation of SIV reservoir 2Health News:LA Galaxy vs. Manchester United Tickets Rose Bowl: Ticket Down Cuts Chevrolet FC Cup Ticket Prices For ManU vs. LA Galaxy in Pasadena on July 23rd 2Health News:LA Galaxy vs. Manchester United Tickets Rose Bowl: Ticket Down Cuts Chevrolet FC Cup Ticket Prices For ManU vs. LA Galaxy in Pasadena on July 23rd 3Health News:Court Overseeing First Ethicon Transvaginal Mesh Lawsuit Trial in New Jersey Upholds $11 Million+ Jury Award, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing First Ethicon Transvaginal Mesh Lawsuit Trial in New Jersey Upholds $11 Million+ Jury Award, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing First Ethicon Transvaginal Mesh Lawsuit Trial in New Jersey Upholds $11 Million+ Jury Award, Bernstein Liebhard LLP Reports 4Health News:Scientists Snipped HIV Out of Human DNA 2Health News:No Change in Heart Attack Rates for Younger U.S. Adults 2Health News:No Change in Heart Attack Rates for Younger U.S. Adults 3
... of Medicine apparently have solved the riddle of why cancer ... mechanism that could lead to better cancer treatments. , ... laboratory in the Duke Department of Pharmacology and Cancer Biology, ... a way to avoid programmed cell death. They make use ...
... Alcon, Inc.,(NYSE: ACL ) announced today that ... PATANASE(R) (olopatadine hydrochloride) nasal spray for,the relief of ... 12,years of age and older. PATANASE(R) nasal spray, ... will be available in May of,this year., ...
... As the State of Nebraska,s Chief,Medical Officer, Joann ... health issues. The same goes for Gary Gorby, ... Medical Center. Right now, both,physicians are focusing on ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/LATU118LOGO ), Dr. Schaefer, 40, ...
... Gift of Mobility Helps Teenager Attend Classes and Take ... Like many,15-year-olds, Rachel Wilhite enjoys hanging out with ... However, she is also struggling with a condition that ... relatively rare dwarfism that,has serious consequences. When the body ...
... Advertising and Medical Education ... Network, ... more than 15 years strategic and business-building,experience, has joined GHG Grey Healthcare ... Grey,Healthcare Group (GHG) is a WPP company and one of the world,s ...
... NEW YORK, April 15 GHG Grey Healthcare ... world,s leading healthcare communications firms,announced that Jennifer Samuels ... Services. Ms. Samuels has a wide range of ... industry, and an in-depth,knowledge of the oncology and ...
Cached Medicine News:Health News:A potential sugar fix for tumors 2Health News:Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 2Health News:Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 3Health News:Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms 4Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 2Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 3Health News:Two Prominent Nebraska Doctors Become Patients in Living Donor Liver Transplant 4Health News:The SCOOTER Store Donates Power Chair to Teenager Struggling With Rare Dwarfism 2Health News:The SCOOTER Store Donates Power Chair to Teenager Struggling With Rare Dwarfism 3Health News:Susan Byrne joins GHG Grey Healthcare Group as EVP, Strategy and Business Development, Europe, a Newly-Created Position 2Health News:Jennifer Samuels Joins GHG Grey Healthcare Group as Executive Vice President, Account Services 2
(Date:7/21/2014)...  EHE International, the recognized leader in preventive medicine ... today announced that Dignity Health Medical Group Nevada, LLC  ... been named an EHE-certified preventive care center. Through Dignity, ... region now have greater access to EHE,s preventive ... "EHE is proud to add Dignity Health ...
(Date:7/21/2014)... 21, 2014 According ... Research "E-Clinical Solution Software Market- Global Industry Analysis, Size, ... global microfluidic device market was valued at USD 3,005 ... a CAGR of 13.8% from 2014 to 2020, to ... 2020. Browse the full E-Clinical Solution Software Market ...
(Date:7/21/2014)... -- By order of the U.S. Bankruptcy Court, Tiger Group,s ... and optical equipment, designer eyeglass frames, and other assets of ... Services LLC. Online bidding opens July 21 at ... auction style, on July 28 beginning at 10:30 a.m. (ET). ... July 25 th and 26 th at 12 ...
Breaking Medicine Technology:EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5Auction Set For Assets Of National Optical Services Company 2
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
... NBIX ) today announced its financial results for ... of 2012, the Company reported net loss of $0.9 million, ... of $2.9 million, or $0.05 income per share, for the ... results is primarily due to the Company,s VMAT2 program moving ...
Cached Medicine Technology:Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
Designed for the clockwise one-hand implantation of the Morcher Capsular Tension Ring....
... the Diagnosys electrophysiology system is the Espion. This ... support a wide variety of stimulators for different ... Function Testing ,The Espion system was designed ... the current standard clinical visual function tests, ERG, ...
... the heart of the Espion2 Electrophysiology system. ... aluminum chassis, real-time DSP, USB control, an ... differential amplifiers. The E2 connects to any ... over standard wi-fi Ethernet. The E2 includes ...
Medicine Products: